行情

ACAD

ACAD

阿卡迪亚
NASDAQ

实时行情|Nasdaq Last Sale

40.13
-1.42
-3.42%
交易中 14:18 01/29 EST
开盘
41.45
昨收
41.55
最高
41.57
最低
40.03
成交量
57.43万
成交额
--
52周最高
53.70
52周最低
21.04
市值
61.62亿
市盈率(TTM)
-22.8245
分时
5日
1月
3月
1年
5年

分析师评级

15位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ACAD 新闻

  • 2 Biotech Stocks to Watch In 2020
  • MotleyFool.com.01/17 14:00
  • ACADIA (ACAD) Up More Than 100% in the Past Year: Here's Why
  • Zacks.01/17 13:45
  • How Did ACADIA Pharmaceuticals Inc. (ACAD) Perform In Comparison to Hedge Fund Favorites in 2019?
  • Insider Monkey.01/10 16:54
  • The 10 Best Healthcare Stocks of the Decade
  • MotleyFool.com.01/07 15:24

更多

所属板块

生物技术和医学研究
-0.03%
制药与医学研究
+0.42%

热门股票

名称
价格
涨跌幅

ACAD 简况

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
展开

Webull提供ACADIA Pharmaceuticals Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。